These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 35643381)

  • 1. A randomized, placebo-controlled, double-blind trial to evaluate efficacy and safety of Shen-Yuan-Dan capsules, a traditional Chinese medicine, for treatment of peri-procedure myocardial injury following percutaneous coronary intervention.
    Li X; Zhang Y; Liu HX; Shang JJ; Zhou Q; Li AY; Lai XL; Xing WL; Jia SH
    Complement Ther Med; 2022 Oct; 69():102841. PubMed ID: 35643381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Shen-Yuan-Dan on Periprocedural Myocardial Injury and the Number of Peripheral Blood Endothelial Progenitor Cells in Patients with Unstable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention.
    Zhang Z; Xing W; Liu H; Zhou Q; Liu X; Shang J
    Evid Based Complement Alternat Med; 2022; 2022():9055585. PubMed ID: 35035512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Risk Factors of Periprocedural Myocardial Injury in Patients with Elective PCI in a TCM Hospital.
    Li X; Zhang HY; Shang JJ; Liu HX; Zhou Q; Lai XL
    Evid Based Complement Alternat Med; 2022; 2022():7158740. PubMed ID: 35368758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    J Am Heart Assoc; 2022 Mar; 11(6):e022937. PubMed ID: 35261279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in East Asian patients undergoing percutaneous coronary intervention: A meta-analysis of fifteen randomized controlled trials.
    Liu J; Zhang B; Chen M; Zheng B
    Medicine (Baltimore); 2021 Jun; 100(25):e26278. PubMed ID: 34160392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Xinyue capsules on patients with coronary heart disease after percutaneous coronary intervention: study protocol for a randomized controlled trial.
    Guo M; Zi MJ; Xi RX; Yang QN; Bai RN; Zhang YS; Wang YH; Wang PL; Shi DZ
    Trials; 2016 Aug; 17():412. PubMed ID: 27538952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet and myocardial protective effect of Shexiang Tongxin Dropping Pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial.
    Lin YJ; Jiao KL; Liu B; Fang L; Meng S
    J Integr Med; 2022 Mar; 20(2):126-134. PubMed ID: 35101369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.
    Furtado RHM; Fagundes AA; Oyama K; Zelniker TA; Tang M; Kuder JF; Murphy SA; Hamer A; Wang H; Keech AC; Giugliano RP; Sabatine MS; Bergmark BA
    Circ Cardiovasc Interv; 2022 Mar; 15(3):e011382. PubMed ID: 35209731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Lipoprotein(a) and Peri-procedural Myocardial Infarction in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.
    Liu Y; Wang W; Song J; Zhang K; Xu B; Li P; Shao C; Yang M; Chen J; Tang YD
    Front Endocrinol (Lausanne); 2020; 11():603922. PubMed ID: 33613445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A traditional Chinese medicine therapy for coronary heart disease after percutaneous coronary intervention: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Chen R; Xiao Y; Chen M; He J; Huang M; Hong X; Liu X; Fu T; Zhang J; Chen L
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30143584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged infusion of bivalirudin after elective percutaneous coronary intervention protects against procedural myocardial injury (a COBER study)-a randomized trial.
    Wu Z; Meng P; Guo Y; You W; Wu X; Ye F
    Sci Rep; 2023 Apr; 13(1):6667. PubMed ID: 37095298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guanxin Danshen Dripping Pills Improve Quality of Life and Cardiovascular Prognoses of CHD Patients after PCI with Anxiety or Depression (GLAD Study): A Randomized Double-Blind Placebo-Controlled Study.
    Wang CL; Huan N; Wang PL; Geng QS; Ma WL; Ma LH; Jiang HY; Meng XP; Zhang DW; Gou XJ; Hu DY; Chen KJ
    Chin J Integr Med; 2023 Mar; 29(3):195-204. PubMed ID: 36301456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The coronary angiography-derived index of microcirculatory resistance predicts perioperative myocardial injury in stable coronary artery disease patients undergoing PCI.
    Zhang B; Zhang Y; Zhang K; Hu K; Shi Z; Ma L
    Heliyon; 2024 Aug; 10(15):e35240. PubMed ID: 39161812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intervention of Compound Xueshuantong Capsule on the incidence of heart failure in patients with acute myocardial infarction after PCI based on the combination of disease and syndrome: A multi-center, randomized, double-blind, controlled trial.
    Yang XD; Shi JX; Liao WC; Cui JY; Jin Z; Liu DL; Chen XL; Li R; Wu H; Luo C; Chu Q; Li R; Wu W; Qing L
    Medicine (Baltimore); 2022 Dec; 101(50):e32311. PubMed ID: 36550849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of serum laboratory parameters with periprocedural myocardial infarction after a primary percutaneous coronary intervention.
    Deng Q; Hou J; Deng X; Zhong Z
    Perfusion; 2023 Mar; 38(2):393-400. PubMed ID: 35038275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
    Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Nowbar AN; Simader FA; Davies JR; O'Kane PD; Haworth P; Routledge H; Kotecha T; Gamma R; Clesham G; Williams R; Din J; Nijjer SS; Curzen N; Ruparelia N; Sinha M; Dungu JN; Ganesananthan S; Khamis R; Mughal L; Kinnaird T; Petraco R; Spratt JC; Sen S; Sehmi J; Collier DJ; Sohaib A; Keeble TR; Cole GD; Howard JP; Francis DP; Shun-Shin MJ; Al-Lamee RK;
    N Engl J Med; 2023 Dec; 389(25):2319-2330. PubMed ID: 38015442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Alprostadil in Microcirculatory Disturbances During Emergency PCI: A Meta-Analysis of Randomized Controlled Trials.
    Chen Y; Wang M; Yang Y; Zeng M
    Am J Cardiovasc Drugs; 2024 Jul; 24(4):547-556. PubMed ID: 38850398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sevoflurane on serum CK-MB levels after percutaneous coronary stent placement: A prospective randomized clinical trial.
    Júnior RR; Nigro C; Braga SN; Sousa AG; Feres F; Costa JR
    J Invasive Cardiol; 2023 Dec; 35(12):. PubMed ID: 38108873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of Tongxin formula after stent implantation for acute coronary syndrome: A multicenter, double-blind, placebo-controlled randomized trial.
    Zhu W; Wang S; Zhang L; Xie FQ; Cheng J; Li XK; Chen W; Yan SY; Feng QM
    Explore (NY); 2024; 20(5):102992. PubMed ID: 38503613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial.
    Xu Y; Li X; Zhang H; Wu Y; Zhang J; Li J; Dou K; Yan H; You S; Yang Y; Liang Y; Xu L; Gao X; Liu C; Dong Q; Zhang W; Song G; Zhang T; Jiang L; Chen G; Tang R; Jin C; Yang J; Yao C; Xian Y; Peterson ED; Gao R; Yang Y
    Am Heart J; 2020 Sep; 227():47-55. PubMed ID: 32679281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.